Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 2, 2003, Pages 165-177

  Khare, Milind ^a   Keady, Deirbhile ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

AZD2563; BMS 247243; Daptomycin; GSQ1530; Methicillin resistancce; Oritavancin; Quinupristin dalfopristin; RWJ 54428; Staphylococcus aureus; Teicoplanin; Tigecycline; Vancomycin

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BMS 247243; CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GLYCOPEPTIDE; GSQ 1530; KETOLIDE; LINEZOLID; LIPOPROTEIN; MACROLIDE; METICILLIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POSIZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; APLASTIC ANEMIA; AREA UNDER THE CURVE; CHILL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEVER; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HEADACHE; HEARING LOSS; HEMOLYTIC ANEMIA; HOSPITAL INFECTION; HUMAN; JAUNDICE; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHLEBITIS; RASH; REVIEW; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0037324388     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.2.165     Document Type: Review

References (52)

1. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. J. Hosp. Infect. (1998) 39:253-290.
2. ROSENBERG J: Methicillin-resistant Staphylococcus aureus (MRSA) in the community: who's watching? Lancet (1995) 346:132-133.
3. TENOVER FC: Implications of vancomycin-resistant Staphylococcus aureus. J. Hosp. Infect. (1999) 43(Suppl.):S3-S7.
4. HAMILTON-MILLER JM: Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection (2002) 30:118-124.
5. BARTLEY J: First case of VRSA identified in Michigan. Infect. Control Hosp. Epidemiol. (2002) 23:480.
6. LINDHOLM DD, MURRAY JS: Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N. Engl. J. Med. (1966) 274:1047-1051.
7. EYKYN S, PHILLIPS I, EVANS J: Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis. Br. Med. J. (1970) 3:80-82.
8. RICE TL: Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns (1992) 18:355-361.
9. WILHELM MP: Vancomycin. Mayo Clin. Proc. (1991) 66:1165-1170.
10. TRABER PG, LEVINE DP: Vancomycin ototoxicity in patient with normal renal function. Ann. Intern. Med. (1981) 95:458-460.
11. APPEL GB, NEU HC: The nephrotoxicity of antimicrobial agents (second of three parts). N. Engl. J. Med. (1977) 296:722-728.
12. HARLAND S, TEBBS SE, ELLIOTT TS: Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother. (1998) 41:273-276.
13. SWANEY SM, AOKI H, GANOZA MC, SHINABARGER DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. (1998) 42:3251-3255.
14. CHAMPNEY WS, MILLER M: Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr. Microbiol. (2002) 44:350-356.
15. STALKER DJ, WAJSZCZUK CP, BATTS DH: Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997) Toronto, Canada: 23-24.
16. WELSHMAN IR: Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Antiinfect. Drugs Chemother. (1998) 16(Suppl. 1):54.
17. STALKER DJ, WAJSZCZUC CP: BATTS DH: Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997) Toronto, Canada: 23-24 (Abstract).
18. PAWSEY SD: U-100766 safety, tolerance and pharmacokinetics after oral and intravenous administration. First European Congress of CShemotherapy (1996):(Abstract).
19. WIENKERS LC: In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (1999):(Abstract).
20. 14C]PNU 100766 to healthy human volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (1998):(Abstract).
21. STALKER DJ: Pharmacokinetics of linezolid in pediatric patients. Clin. Infect. Dis. (1998) 27:(Abstract).
22. LOVERING AM, ZHANG J, BANNISTER GC et al.: Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. (2002) 50:73-77.
23. HAU T: Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur. J. Clin. Microbiol. Infect. Dis. (2002) 21:491-498.
24. DIEKEMA DJ, JONES RN: Oxazolidinone antibiotics. Lancet (2001) 358:1975-1982.
25. STEVENS DL, HERR D, LAMPIRIS H, HUNT JL, BATTS DH, HAFKIN B: Linezolid versus vancomycm for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. (2002) 34:1481-1490.
26. GERSON SL, KAPLAN SL, BRUSS JB, LE V, ARELLANO FM, HAFKIN B, KUTER DJ: Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. (2002) 46:2723-2726.
27. MONSON T, SCHICHMAN SA, ZENT CS: Linezolid-induced pure red blood cell aplasia. Clin. Infect. Dis. (2002) 35:E29-E31.
28. HALPERN M: Linezolid-induced pancytopenia. Clin. Infect. Dis. (2002) 35:347-348.
29. AUCKLAND C, TEARE L, COOKE F et al.: Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. (2002) 50:743-746.
30. JOHNSON AP, TYSALL L, STOCKDALE MW et al.: Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. (2002) 21:751-754.
31. PILLAI SK, SAKOULAS G, WENNERSTEN C et al.: Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. (2002) 186:1603-1607.
32. FLUIT AV, SCHMITZ FJ, VERHOEF J, MILATOVIC D: In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci. J. Antimicrob. Chemother. (2002) 50:271-276.
33. ANDEREGG TR, BIEDENBACH DJ, JONES RN: In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob. Agents Chemother. (2002) 46:2662-2664.
34. EDWARDS: AZD 2563: A novel oxazolidine. 41st Interscience conference an Antimicrobial agents and chemotherapy. Chicago, Illinois (2001):(Abstract 8).
35. FAGON JY: Randomized, comparative, multicenter, open study of quinupristin/dalfopristin plus aztreonam versus vancomycin plus aztreonam in the treatment of Gram-positive nosocomial pneumonia. Programme and Abstracts of the Twentieth International Congress of Chemotherapy. (1997) Sydney, Australia:44.
36. LIVERMORE DM: Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother. (2000) 46:347-350.
37. JOHNSON AP, LIVERMORE DM: Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal. Lancet (1999) 354:2012-2013.
38. SANDER A, BEIDERLINDEN M, SCHMID EN, PETERS J: Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med. (2002) 28:1157-1160.
39. GOFF DA, SIERAWSKI SJ: Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant Gram-positive infections. Pharmacotherapy (2002) 22:748-758.
40. LOEFFLER AM, DREW RH, PERFECT JR et al.: Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr. Infect. Dis. J. (2002) 21:950-956.
41. LUH KT, HSUEH PR, TENG LJ et al.: Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. (2000) 44:3374-3380.
42. ALLEN GP, CHA R, RYBAK MJ: In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (2002) 46:2606-2612.
43. BOSWELL T: Oral treatment of MRSA infection. CPD Infection (1999) 1:28-30.
44. PETERSEN PJ, BRADFORD PA, WEISS WJ, MURPHY TM, SUM PE, PROJAN SJ: In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46:2595-2601.
45. JOHNSON AP, WARNER M, LIVERMORE DM: Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J. Antimicrob. Chemother. (2000) 45:225-230.
46. SNYDMAN DR, JACOBUS NV, MCDERMOTT LA, LONKS JR, BOYCE JM: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2000) 44:3447-3450.
47. VERHOEF J: Daptomycin: a new agent to treat serious Gram-positive infections. 12th ECCMID (2002).
48. JOHNSON AP, WARNER M, CARTER M, LIVERMORE DM: In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant Gram-positive cocci. Antimicrob. Agents Chemother. (2002) 46:321-326.
49. SWENSON JM, TENOVER FC: In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. (2002) 49:845-850.
50. FUNG-TOMC JC, CLARK J, MINASSIAN B et al.: In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob. Agents Chemother. (2002) 46:971-976.
51. BIGNARDI GE, WOODFORD N, CHAPMAN A, JOHNSON AP, SPELLER DC: Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillin resistance. J. Antimicrob. Chemother. (1996) 37:53-63.
52. GE Y, DIFUNTORUM S, TOUAMI S et al.: In vitro antimicrobial activity of GSQ1530, a new heteroaromatic polycyclic compound. Antimicrob. Agents Chemother. (2002) 46:3168-3174.